Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 22Recruiting 21Active not recruiting 11Terminated 5Unknown 3Not yet recruiting 3Withdrawn 1No longer available 1

Sponsor Class

OTHER 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1Gastrointestinal Neoplasms 1Disease Resistance 1Breast Neoplasms 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × alectinib × Clear all
NCT04591431 2023-10-03

ROME

Fondazione per la Medicina Personalizzata

Phase 2 Unknown
400 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04708639 2021-02-02

MonAlec

Aarhus University Hospital

Unknown
40 enrolled
Thoracic

Lung Neoplasms, Disease Resistance

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Sungkyunkwan University

Unknown
4,724 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡